We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allscripts (MDRX) Completes Sale of CarePort Health Business
Read MoreHide Full Article
Allscripts Healthcare Solution Inc. (MDRX - Free Report) recently announced the completion of the previously-announced sale of CarePort business to WellSky Corporation on Dec 31, 2020, for an amount of $1.35 billion. On Oct 13, 2020, Allscripts entered into a definitive agreement with WellSky to sell its CarePort Health (“CarePort”) business – a leading care coordination software company that helps in the management of patient transitions through different settings of care.
For investors’ note, WellSky is a global healthcare software technology company with an objective to develop, implement and support clinical management marketed to healthcare industry.
The completion of the sale should boost Allscripts’ Population Health segment.
Significance of the Deal
The agreement is hugely beneficial for Allscripts with respect to delivering substantial value for its shareholders and providing the benefit of sustained investment under new and robust ownership to customers at CarePort. Further, this transaction will help Allscripts to boost its commitment toward its core business.
Following the closure of the deal, Allscripts anticipates to use the net after-tax proceeds from the sale for investment in its solutions, while deleveraging its balance sheet and supporting crucial share buybacks.
Another Notable Divestment
In October 2020, Allscripts announced the completion of the previously-announced sale of its EPSi business to Strata Decision Technology (Strata) for $365 million. Notably, on Jul 30, 2020, Allscripts entered into a definitive agreement with Strata to sell EPSi — a leading provider of decision support and planning tools for hospitals and health systems.
Industry Prospects
Per the report by Grand View Research, the global healthcare information technology (IT) market size was valued at $67.5 billion in 2019 and is expected to see a (CAGR) of 10.3% by 2027. Growing demand for preventive care owing to increase in chronic diseases globally coupled with a rise in funding for various healthcare start-ups is driving the market growth.
Price Performance
Shares of Allscripts have gained 47.9% in a year’s time compared with industry’s growth of 25.2%.
Zacks Rank and Key Picks
Currently, Allscripts carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space include Stryker Corporation (SYK - Free Report) , Owens & Minor Inc. (OMI - Free Report) and Quidel Corporation (QDEL - Free Report) . While both Owens & Minor and Quidel sport a Zacks Rank #1 (Strong Buy), Stryker carries a Zacks Rank of 2 (Buy). You can see the complete list of Zacks #1 Rank stocks here.
Stryker has a projected long-term earnings growth rate of 9.6%.
Owens & Minor has an anticipated long-term earnings growth rate of 45.20%
Quidel has a projected long-term earnings growth rate of 25%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Allscripts (MDRX) Completes Sale of CarePort Health Business
Allscripts Healthcare Solution Inc. (MDRX - Free Report) recently announced the completion of the previously-announced sale of CarePort business to WellSky Corporation on Dec 31, 2020, for an amount of $1.35 billion. On Oct 13, 2020, Allscripts entered into a definitive agreement with WellSky to sell its CarePort Health (“CarePort”) business – a leading care coordination software company that helps in the management of patient transitions through different settings of care.
For investors’ note, WellSky is a global healthcare software technology company with an objective to develop, implement and support clinical management marketed to healthcare industry.
The completion of the sale should boost Allscripts’ Population Health segment.
Significance of the Deal
The agreement is hugely beneficial for Allscripts with respect to delivering substantial value for its shareholders and providing the benefit of sustained investment under new and robust ownership to customers at CarePort. Further, this transaction will help Allscripts to boost its commitment toward its core business.
Following the closure of the deal, Allscripts anticipates to use the net after-tax proceeds from the sale for investment in its solutions, while deleveraging its balance sheet and supporting crucial share buybacks.
Another Notable Divestment
In October 2020, Allscripts announced the completion of the previously-announced sale of its EPSi business to Strata Decision Technology (Strata) for $365 million. Notably, on Jul 30, 2020, Allscripts entered into a definitive agreement with Strata to sell EPSi — a leading provider of decision support and planning tools for hospitals and health systems.
Industry Prospects
Per the report by Grand View Research, the global healthcare information technology (IT) market size was valued at $67.5 billion in 2019 and is expected to see a (CAGR) of 10.3% by 2027. Growing demand for preventive care owing to increase in chronic diseases globally coupled with a rise in funding for various healthcare start-ups is driving the market growth.
Price Performance
Shares of Allscripts have gained 47.9% in a year’s time compared with industry’s growth of 25.2%.
Zacks Rank and Key Picks
Currently, Allscripts carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space include Stryker Corporation (SYK - Free Report) , Owens & Minor Inc. (OMI - Free Report) and Quidel Corporation (QDEL - Free Report) . While both Owens & Minor and Quidel sport a Zacks Rank #1 (Strong Buy), Stryker carries a Zacks Rank of 2 (Buy). You can see the complete list of Zacks #1 Rank stocks here.
Stryker has a projected long-term earnings growth rate of 9.6%.
Owens & Minor has an anticipated long-term earnings growth rate of 45.20%
Quidel has a projected long-term earnings growth rate of 25%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>